VU Research Portal Alzheimer PEThology Ossenkoppele, R. 2013 document version Publisher's PDF, also known as Version of record Link to publication in VU Research Portal citation for published version (APA) Ossenkoppele, R. (2013). Alzheimer PEThology. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. E-mail address: [email protected] Download date: 02. Oct. 2021 ALZHEIMER PETHOLOGY The studies described in this thesis were carried out at the Alzheimer Center VUmc and Department of Radiology & Nuclear Medicine, embedded in the neurodegeneration research program of the Neuroscience Campus Amsterdam. Part of this research was performed within the framework of CTMM, the Center for Translational Molecular Medicine (www.ctmm.nlHTU ), UTH project LeARN. The Alzheimercenter Vumc is supported by Innovatiefonds Ziektekostenverzekeraars and by unrestricted grants to the Stichting Vumc Fonds from: AEGON Nederland NV, Ars Donandi Kas Bank Welzijnsfonds, Heer en Mw Capitain, Heineken Nederland NV, Nationale Nederlanden, Janssen Cilag NV, Gebroeders Boeschen, Genootschap Steun Alzheimercentrum, Kroonenberg Groep, KLM Royal Dutch Airlines, KPMG/Plexus, Marcel Boekhoorn, Nutricia Nederland, Onvergetelijke vrienden Alzheimercentrum, RABO Bank Amsterdam, SNS Reaal, Soroptimisten Bussum e.o, Stichting ITON, Stichting De Merel, Stichting ZABAWAS, Stichting Alzheimer Nederland, Stichting Dioraphte, Stichting Mooiste Contact Fonds KPN, Stichting Buytentwist, Twentse Kabel Holding, Ton Aan de Stegge, van Leeuwen‐Rietberg stichting, and many kind individual donors! ISBN: 978‐94‐6108‐430‐9 Printing: Gildeprint drukkerijen Layout: Rik Ossenkoppele & Robbert‐Coen Koreman Cover design: Robbert‐Coen Koreman, Fieke Ossenkoppele & Lenie Ossenkoppele. Copyright © by R. Ossenkoppele, all rights reserved. Publication of this thesis has been accomplished with gratefully acknowledged financial support, provided by Internationale Stichting Alzheimer Onderzoek, Alzheimer Nederland, Pfizer, Nutricia advanced medical nutrition, and CTMM LeARN. VRIJE UNIVERSITEIT Alzheimer PEThology ACADEMISCH PROEFSCHRIFT ter verkrijging van de graad Doctor aan de Vrije Universiteit Amsterdam, op gezag van de rector magnificus prof.dr. L.M. Bouter, in het openbaar te verdedigen ten overstaan van de promotiecommissie van de Faculteit der Geneeskunde op woensdag 8 mei 2013 om 13.45 uur in de aula van de universiteit, De Boelelaan 1105 door Rik Ossenkoppele geboren te Uithoorn promotoren: prof.dr. Ph. Scheltens prof.dr. A.A. Lammertsma copromotoren: dr. B.N.M. van Berckel dr. W.M. van der Flier “Life is what happens to you, while you’re busy making other plans” John Lennon (1940-1980) CONTENTS Chapter 1 General introduction and Outline 9 Chapter 2 Longitudinal imaging of Alzheimer pathology 19 11 2.1 Longitudinal amyloid imaging using [P C]PIB: P 20 Methodological considerations 2.2 Longitudinal imaging of Alzheimer pathology 38 11 18 18 using [P C]PIB, [P P F]FDDNP and [P P F]FDG PET P Chapter 3 Molecular imaging in cognitively normal elderly 59 Is verbal episodic memory in elderly with amyloid deposits preserved through altered neuronal function? Chapter 4 Molecular imaging in AD: mechanisms underlying 81 clinical heterogeneity 4.1 Amyloid burden and metabolic function in early‐onset 82 Alzheimer’s disease: parietal lobe involvement 4.2 Differential effect of APOE genotype on amyloid load 108 and glucose metabolism in AD dementia Chapter 5 Clinical application of molecular imaging 125 5.1 Impact of molecular on the diagnostic process 126 in a memory clinic 5.2 Amyloid imaging in prodromal Alzheimer’s disease 144 Chapter 6 General discussion, summary & future perspectives 151 Addendum Nederlandse samenvatting 167 List of publications Hall of fame Alzheimer center Curriculum vitea Dankwoord Chapter 1 General introduction Aims Thesis outline 1| Introduction GENERAL INTRODUCTION Until recently, confirmation of Alzheimer’s disease (AD) pathology was only possible at post‐mortem examination of the brain or with a brain biopsy. The development of positron emission tomography (PET) tracers to detect amyloid plaque deposition in vivo, like Pittsburgh compound‐B (PIB), caused a major paradigm shift in diagnostic thinking and contributes to the general understanding of neurodegenerative disorders. Several 11 18 biomarkers, including [P C]PIB P and [P F]fluorodeoxyglucose P (FDG) PET, are now incorporated in diagnostic criteria for the diagnosis of dementia and the concept of “preclinical” or “presymptomatic” AD has been revised. This thesis focuses on the relationships between amyloid deposition, glucose metabolism and cognition in a spectrum encompassing presymptomatic AD, prodromal AD and AD dementia. Alzheimer’s disease AD is a progressive neurodegenerative disorder that affects approximately 250.000 people in the Netherlands and 35 million individuals worldwide [1]. Despite extensive research, AD is currently incurable and without a major breakthrough the number of patients will possibly exceed 115 million by 2050. AD places a large burden on caregivers and is the single most costly disease in the Netherlands. The growing socio‐economic impact of AD on society demands scientific progress towards an efficient treatment of the disease. Patients with AD usually present with episodic memory impairment, followed by progressive decline in language, visuo‐spatial and executive functions. In early‐onset AD (disease onset before the age of 65), however, approximately 30% initially shows non‐ memory deficits [2‐5]. This may hinder diagnostic decision making, as there is substantial phenotypical overlap with other forms of dementia in young patients. Another factor that has impact on the clinical manifestation of AD is apolipoprotein E (APOE) genotype [6,7]. The mechanisms underlying clinical heterogeneity are currently not well understood [8]. Regardless of the clinical presentation, at least two cognitive domains should be affected in addition to interference with activities of daily living (ADL) to fulfill diagnostic criteria for AD [9]. These criteria were recently revised and now take into account biomarker 10 1| Introduction 11 18 findings such as [P C]PIB and [P P F]FDG PET and structural MRI to establish the likelihood P of the clinical diagnosis [10]. The clinical stage of dementia is preceded by a prodromal phase, often referred to as mild cognitive impairment (MCI). MCI patients have significant cognitive deficits but do not experience ADL interference [11]. The annual rate of progression from MCI to AD is 10‐ 15% [12]. Not all MCI patients convert to AD, as in some cases depression, stress or a non‐ AD type of dementia may explain their condition. In the prospect of disease‐modifying treatment it is important to identify patients who are in the prodromal stage of AD. To facilitate an earlier diagnosis of AD, research criteria were proposed that incorporate biomarker findings to establish a diagnosis of “prodromal AD” or “MCI due to AD” in MCI patients [13,14]. It still has to be determined, however, whether abnormal biomarkers are indeed indicative of clinical progression in MCI patients. At an even earlier stage, advances in neuroimaging and other biomarkers were translated into remodeling the concept “preclinical” or “asymptomatic” AD for research purposes [15]. The major risk factors for AD, age and APOE genotype [16‐18], are strongly associated with greater AD pathology in cognitively normal elderly [19‐22]. Emerging data in these individuals suggest that presence of AD pathology is associated with functional and structural brain changes in a pattern consistent with observations in MCI and AD patients [23‐33]. This has led to the notion that cognitively normal individuals with cerebral amyloidosis are at risk for AD. Additional signs of neurodegeneration (e.g. increased CSF‐tau, glucose hypometabolism or brain atrophy in AD specific regions) or subtle cognitive deficits increase the likelihood of rapid emergence of cognitive symptoms and clinical decline within several years [15]. An intriguing and still unresolved question related to this topic is how some elderly are capable of withstanding extensive AD pathology in their brain and preserve, at least temporarily, normal cognitive function. The neuropathological cascade of Alzheimer’s disease The neuropathological characteristics underlying AD are extracellular senile plaques consisting of amyloid‐β (Aβ) and intracellular neurofibrillary tangles consisting of hyperphosphorylated tau. Aβ is a peptide that is produced by cleavage of the larger protein Aβ precursor protein (APP) by β‐ or γ‐secretase [34]. Amyloid plaque depositions 11 1| Introduction are widely distributed throughout the cortex with relative sparing of the medial temporal lobe [35]. It is thought that neurofibrillary tangle